Welcome to our dedicated page for LEMAITRE VASCULAR SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LEMAITRE VASCULAR's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LEMAITRE VASCULAR's regulatory disclosures and financial reporting.
LEMAITRE VASCULAR INC President and Director David B. Roberts reported routine compensation-related transactions involving dividend equivalent rights on June 4, 2026. These are derivative awards that mirror dividends on previously granted stock-based awards rather than open-market trades.
The filing shows nine acquisitions coded as grants, each adding small fractional dividend equivalent rights tied to restricted stock unit and performance share unit awards granted on December 12, 2022, December 8, 2023, December 6, 2024, February 18, 2025, and December 10, 2025. Each dividend equivalent right is the economic equivalent of one share of common stock and vests proportionately with its underlying award. No shares were bought or sold in the market.
Kamke Trent G reported acquisition or exercise transactions in this Form 4 filing.
LeMaitre Vascular Inc. senior vice president of operations Trent G. Kamke reported multiple small awards of dividend equivalent rights on Dividend Equivalent Rights instruments. All seven transactions on June 4, 2026 are coded as grants or awards, reflecting compensation-related accruals rather than market purchases or sales.
Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and accrued on previously granted restricted stock unit and performance share unit awards from December 2022, December 2023, December 2024, and December 2025. The rights vest proportionately with the underlying equity awards, and there were no open-market buys or sells disclosed in this filing.
LEMAITRE VASCULAR INC Chairman and CEO George W. LeMaitre reported a mix of estate-planning and compensation-related equity movements in company securities. He made a bona fide gift of 11,974 shares of common stock, after which his direct holdings stood at 1,418,045 common shares. A related irrevocable life insurance trust for the benefit of his children holds 45,374 common shares, and he disclaims beneficial ownership except for any pecuniary interest. In addition, he received several small grants of dividend equivalent rights tied to prior restricted stock unit and performance share unit awards, each economically equivalent to one share of common stock and vesting proportionately with the underlying awards.
LeMaitre Vascular, Inc. reported the results of its 2026 Annual Meeting of Stockholders. A total of 22,847,798 shares were entitled to vote as of April 6, 2026, and 21,336,301 shares were represented in person or by proxy.
Stockholders elected two Class II directors to three-year terms: David B. Roberts received 18,888,412 votes for and 1,250,012 withheld, while John A. Roush received 14,229,071 votes for and 5,909,353 withheld. An advisory vote approved executive compensation with 19,311,813 votes for and 813,052 against. Stockholders also ratified Grant Thornton LLP as independent registered public accounting firm for 2026 with 21,220,412 votes for and 108,474 against.
LeMaitre Vascular, Inc. Schedule 13G/A shows George W. LeMaitre beneficially owns 1,465,235 shares of common stock, equal to 6.4% of the class. The filing states there were 22,847,733 shares outstanding as of March 31, 2026. The reported amount includes 6,847 shares subject to options exercisable within 60 days of March 31, 2026.
LeMaitre Vascular Chairman and CEO George W. LeMaitre reported open-market sales of company stock. On May 7 he sold 18,600 shares of common stock at a weighted average price of $107.6351 per share, and on May 8 he sold 27,881 shares at a weighted average price of $108.6905 per share.
After these direct sales, he continued to hold 1,430,019 shares directly. The filing also shows 33,400 shares held indirectly by the “LeMaitre Irrevocable Life Insurance Trust of 2025,” for the benefit of his children, where he disclaims beneficial ownership except for any pecuniary interest.
LeMaitre Vascular Senior Vice President of Operations Trent G. Kamke sold 2,928 shares of Common Stock in an open-market transaction on May 8, 2026. The weighted average sale price was $106.9969 per share, with trades ranging from $105.32 to $107.46. Following this sale, Kamke directly holds 3,749 shares.
LEMAITRE VASCULAR director Bridget A. Ross reported an exercise-and-sale transaction in company stock. On May 7, 2026, she exercised stock options to acquire a total of 5,044 shares of Common Stock, including 1,600 shares at an exercise price of $47.19 per share and 3,444 shares at $48.60 per share.
On the same date, she completed an open‑market sale of 5,044 Common Stock shares at a weighted average price of $111.0956 per share, executed in multiple trades ranging from $111.00 to $111.30. Following these transactions, she directly owns 3,942 Common Stock shares, and the reported options tied to these exercises are fully vested and, after exercise, no longer outstanding.
LeMaitre Vascular director Lawrence J. Jasinski reported an exercise-and-sell transaction in company stock. On May 7, 2026, he sold 3,943 shares of common stock in an open-market sale at $110.00 per share, leaving him with 4,714 directly held shares afterward.
On the same date, he exercised stock options to acquire a total of 2,858 common shares at exercise prices of $101.12, $54.65, and $47.19 per share. Related option entries show remaining option positions in multiple grants following these exercises. Overall, the filing reflects a combination of option exercises and a net sale of shares.
LMAT filing reports restricted common stock vesting events and two Rule 144 sales by Trent G. Kamke. The filing lists vested restricted shares dated 03/14/2025 and 03/03/2025, and two reported dispositions on 02/27/2026 and 03/11/2026.